The Market Reports
Call: +1-631-407-1315 / +91-750-729-1479
Email: sales@themarketreports.com
Gene Therapy for Age-related Macular Degeneration-Global Market Insights and Sales Trends 2024
Synopsis
Macular degeneration is a condition in which, macula, a part of the retina, gets damaged or deteriorated. This condition usually affects individuals who are aged 50 years and above and therefore, it is called age-related macular degeneration (AMD). AMD is the leading cause of vision loss and is directly related to the advancement of age. But smoking also plays a vital role in causing AMD. AMD is characterized by the presence of a blurred area near the center of vision that leads to distorted vision. There are two different types of AMD, including dry (atrophic) AMD (dAMD) and wet (neovascular/exudative) AMD (wAMD). The dAMD is the most common type of AMD and accounts for almost 80%-90% of the overall AMD cases.
The global Gene Therapy for Age-related Macular Degeneration market size is expected to reach US$ million by 2029, growing at a CAGR of % from 2023 to 2029. The market is mainly driven by the significant applications of Gene Therapy for Age-related Macular Degeneration in various end use industries. The expanding demands from the Monotherapy and Combination Therapy, are propelling Gene Therapy for Age-related Macular Degeneration market. Subretinal, one of the segments analysed in this report, is projected to record % CAGR and reach US$ million by the end of the analysis period. Growth in the Intravitreal segment is estimated at % CAGR for the next seven-year period.
The global pharmaceutical market is 1475 billion USD in 2022, growing at a CAGR of 5% during the next six years. The pharmaceutical market includes chemical drugs and biological drugs. For biologics is expected to 381 billion USD in 2022. In comparison, the chemical drug market is estimated to increase from 1005 billion in 2018 to 1094 billion U.S. dollars in 2022. The pharmaceutical market factors such as increasing demand for healthcare, technological advancements, and the rising prevalence of chronic diseases, increase in funding from private & government organizations for development of pharmaceutical manufacturing segments and rise in R&D activities for drugs. However, the industry also faces challenges such as stringent regulations, high costs of research and development, and patent expirations. Companies need to continuously innovate and adapt to these challenges to stay competitive in the market and ensure their products reach patients in need. Additionally, the COVID-19 pandemic has highlighted the importance of vaccine development and supply chain management, further emphasizing the need for pharmaceutical companies to be agile and responsive to emerging public health needs.
Report Objectives
This report provides market insight on the different segments, by players, by Type, by Application. Market size and forecast (2018-2029) has been provided in the report. The primary objectives of this report are to provide 1) global market size and forecasts, growth rates, market dynamics, industry structure and developments, market situation, trends; 2) global market share and ranking by company; 3) comprehensive presentation of the global market for Gene Therapy for Age-related Macular Degeneration, with both quantitative and qualitative analysis through detailed segmentation; 4) detailed value chain analysis and review of growth factors essential for the existing market players and new entrants; 5) emerging opportunities in the market and the future impact of major drivers and restraints of the market.
Key Features of The Study:
This report provides in-depth analysis of the global Gene Therapy for Age-related Macular Degeneration market, and provides market size (US$ million) and CAGR for the forecast period (2023-2029), considering 2022 as the base year.
This report profiles key players in the global Gene Therapy for Age-related Macular Degeneration market based on the following parameters - company details (found date, headquarters, manufacturing bases), products portfolio, Gene Therapy for Age-related Macular Degeneration sales data, market share and ranking.
This report elucidates potential market opportunities across different segments and explains attractive investment proposition matrices for this market.
This report illustrates key insights about market drivers, restraints, opportunities, market trends, regional outlook.
Key companies of Gene Therapy for Age-related Macular Degeneration covered in this report include RetroSense Therapeutics, REGENXBIO and AGTC, etc.
The global Gene Therapy for Age-related Macular Degeneration market report caters to various stakeholders in this industry including investors, suppliers, product players, distributors, new entrants, and financial analysts.
Market Segmentation
Company Profiles:
RetroSense Therapeutics
REGENXBIO
AGTC
Global Gene Therapy for Age-related Macular Degeneration market, by region:
North America (U.S., Canada, Mexico)
Europe (Germany, France, UK, Italy, etc.)
Asia Pacific (China, Japan, South Korea, Southeast Asia, India, etc.)
South America (Brazil, etc.)
Middle East and Africa (Turkey, GCC Countries, Africa, etc.)
Global Gene Therapy for Age-related Macular Degeneration market, Segment by Type:
Subretinal
Intravitreal
Global Gene Therapy for Age-related Macular Degeneration market, by Application
Monotherapy
Combination Therapy
Core Chapters
Chapter One: Introduces the report scope of the report, executive summary of global and regional market size and CAGR for the history and forecast period (2018-2023, 2024-2029). It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter Two: Provides the analysis of various market segments by Type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter Three: Provides the analysis of various market segments by Application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter Four: Detailed analysis of Gene Therapy for Age-related Macular Degeneration companies’ competitive landscape, revenue, market share and ranking, latest development plan, merger, and acquisition information, etc.
Chapter Five: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product introduction, revenue, recent development, etc.
Chapter Six, Seven, Eight, Nine and Ten: North America, Europe, Asia Pacific, Latin America, Middle East & Africa, revenue by country.
Chapter Eleven: this section also introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by companies in the industry, and the analysis of relevant policies in the industry.
Chapter Twelve: Research Finding/Conclusion
Macular degeneration is a condition in which, macula, a part of the retina, gets damaged or deteriorated. This condition usually affects individuals who are aged 50 years and above and therefore, it is called age-related macular degeneration (AMD). AMD is the leading cause of vision loss and is directly related to the advancement of age. But smoking also plays a vital role in causing AMD. AMD is characterized by the presence of a blurred area near the center of vision that leads to distorted vision. There are two different types of AMD, including dry (atrophic) AMD (dAMD) and wet (neovascular/exudative) AMD (wAMD). The dAMD is the most common type of AMD and accounts for almost 80%-90% of the overall AMD cases.
The global Gene Therapy for Age-related Macular Degeneration market size is expected to reach US$ million by 2029, growing at a CAGR of % from 2023 to 2029. The market is mainly driven by the significant applications of Gene Therapy for Age-related Macular Degeneration in various end use industries. The expanding demands from the Monotherapy and Combination Therapy, are propelling Gene Therapy for Age-related Macular Degeneration market. Subretinal, one of the segments analysed in this report, is projected to record % CAGR and reach US$ million by the end of the analysis period. Growth in the Intravitreal segment is estimated at % CAGR for the next seven-year period.
The global pharmaceutical market is 1475 billion USD in 2022, growing at a CAGR of 5% during the next six years. The pharmaceutical market includes chemical drugs and biological drugs. For biologics is expected to 381 billion USD in 2022. In comparison, the chemical drug market is estimated to increase from 1005 billion in 2018 to 1094 billion U.S. dollars in 2022. The pharmaceutical market factors such as increasing demand for healthcare, technological advancements, and the rising prevalence of chronic diseases, increase in funding from private & government organizations for development of pharmaceutical manufacturing segments and rise in R&D activities for drugs. However, the industry also faces challenges such as stringent regulations, high costs of research and development, and patent expirations. Companies need to continuously innovate and adapt to these challenges to stay competitive in the market and ensure their products reach patients in need. Additionally, the COVID-19 pandemic has highlighted the importance of vaccine development and supply chain management, further emphasizing the need for pharmaceutical companies to be agile and responsive to emerging public health needs.
Report Objectives
This report provides market insight on the different segments, by players, by Type, by Application. Market size and forecast (2018-2029) has been provided in the report. The primary objectives of this report are to provide 1) global market size and forecasts, growth rates, market dynamics, industry structure and developments, market situation, trends; 2) global market share and ranking by company; 3) comprehensive presentation of the global market for Gene Therapy for Age-related Macular Degeneration, with both quantitative and qualitative analysis through detailed segmentation; 4) detailed value chain analysis and review of growth factors essential for the existing market players and new entrants; 5) emerging opportunities in the market and the future impact of major drivers and restraints of the market.
Key Features of The Study:
This report provides in-depth analysis of the global Gene Therapy for Age-related Macular Degeneration market, and provides market size (US$ million) and CAGR for the forecast period (2023-2029), considering 2022 as the base year.
This report profiles key players in the global Gene Therapy for Age-related Macular Degeneration market based on the following parameters - company details (found date, headquarters, manufacturing bases), products portfolio, Gene Therapy for Age-related Macular Degeneration sales data, market share and ranking.
This report elucidates potential market opportunities across different segments and explains attractive investment proposition matrices for this market.
This report illustrates key insights about market drivers, restraints, opportunities, market trends, regional outlook.
Key companies of Gene Therapy for Age-related Macular Degeneration covered in this report include RetroSense Therapeutics, REGENXBIO and AGTC, etc.
The global Gene Therapy for Age-related Macular Degeneration market report caters to various stakeholders in this industry including investors, suppliers, product players, distributors, new entrants, and financial analysts.
Market Segmentation
Company Profiles:
RetroSense Therapeutics
REGENXBIO
AGTC
Global Gene Therapy for Age-related Macular Degeneration market, by region:
North America (U.S., Canada, Mexico)
Europe (Germany, France, UK, Italy, etc.)
Asia Pacific (China, Japan, South Korea, Southeast Asia, India, etc.)
South America (Brazil, etc.)
Middle East and Africa (Turkey, GCC Countries, Africa, etc.)
Global Gene Therapy for Age-related Macular Degeneration market, Segment by Type:
Subretinal
Intravitreal
Global Gene Therapy for Age-related Macular Degeneration market, by Application
Monotherapy
Combination Therapy
Core Chapters
Chapter One: Introduces the report scope of the report, executive summary of global and regional market size and CAGR for the history and forecast period (2018-2023, 2024-2029). It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter Two: Provides the analysis of various market segments by Type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter Three: Provides the analysis of various market segments by Application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter Four: Detailed analysis of Gene Therapy for Age-related Macular Degeneration companies’ competitive landscape, revenue, market share and ranking, latest development plan, merger, and acquisition information, etc.
Chapter Five: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product introduction, revenue, recent development, etc.
Chapter Six, Seven, Eight, Nine and Ten: North America, Europe, Asia Pacific, Latin America, Middle East & Africa, revenue by country.
Chapter Eleven: this section also introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by companies in the industry, and the analysis of relevant policies in the industry.
Chapter Twelve: Research Finding/Conclusion
Index1 Market Overview of Gene Therapy for Age-related Macular Degeneration
1.1 Gene Therapy for Age-related Macular Degeneration Market Overview
1.1.1 Gene Therapy for Age-related Macular Degeneration Product Scope
1.1.2 Gene Therapy for Age-related Macular Degeneration Market Status and Outlook
1.2 Global Gene Therapy for Age-related Macular Degeneration Market Size Overview by Region 2018 VS 2022 VS 2029
1.3 Global Gene Therapy for Age-related Macular Degeneration Market Size by Region (2018-2029)
1.4 Global Gene Therapy for Age-related Macular Degeneration Historic Market Size by Region (2018-2023)
1.5 Global Gene Therapy for Age-related Macular Degeneration Market Size Forecast by Region (2024-2029)
1.6 Key Regions, Gene Therapy for Age-related Macular Degeneration Market Size (2018-2029)
1.6.1 North America Gene Therapy for Age-related Macular Degeneration Market Size (2018-2029)
1.6.2 Europe Gene Therapy for Age-related Macular Degeneration Market Size (2018-2029)
1.6.3 Asia-Pacific Gene Therapy for Age-related Macular Degeneration Market Size (2018-2029)
1.6.4 Latin America Gene Therapy for Age-related Macular Degeneration Market Size (2018-2029)
1.6.5 Middle East & Africa Gene Therapy for Age-related Macular Degeneration Market Size (2018-2029)
2 Gene Therapy for Age-related Macular Degeneration Market by Type
2.1 Introduction
2.1.1 Subretinal
2.1.2 Intravitreal
2.2 Global Gene Therapy for Age-related Macular Degeneration Market Size by Type: 2018 VS 2022 VS 2029
2.2.1 Global Gene Therapy for Age-related Macular Degeneration Historic Market Size by Type (2018-2023)
2.2.2 Global Gene Therapy for Age-related Macular Degeneration Forecasted Market Size by Type (2024-2029)
2.3 Key Regions Market Size by Type
2.3.1 North America Gene Therapy for Age-related Macular Degeneration Revenue Breakdown by Type (2018-2029)
2.3.2 Europe Gene Therapy for Age-related Macular Degeneration Revenue Breakdown by Type (2018-2029)
2.3.3 Asia-Pacific Gene Therapy for Age-related Macular Degeneration Revenue Breakdown by Type (2018-2029)
2.3.4 Latin America Gene Therapy for Age-related Macular Degeneration Revenue Breakdown by Type (2018-2029)
2.3.5 Middle East and Africa Gene Therapy for Age-related Macular Degeneration Revenue Breakdown by Type (2018-2029)
3 Gene Therapy for Age-related Macular Degeneration Market Overview by Application
3.1 Introduction
3.1.1 Monotherapy
3.1.2 Combination Therapy
3.2 Global Gene Therapy for Age-related Macular Degeneration Market Size by Application: 2018 VS 2022 VS 2029
3.2.1 Global Gene Therapy for Age-related Macular Degeneration Historic Market Size by Application (2018-2023)
3.2.2 Global Gene Therapy for Age-related Macular Degeneration Forecasted Market Size by Application (2024-2029)
3.3 Key Regions Market Size by Application
3.3.1 North America Gene Therapy for Age-related Macular Degeneration Revenue Breakdown by Application (2018-2029)
3.3.2 Europe Gene Therapy for Age-related Macular Degeneration Revenue Breakdown by Application (2018-2029)
3.3.3 Asia-Pacific Gene Therapy for Age-related Macular Degeneration Revenue Breakdown by Application (2018-2029)
3.3.4 Latin America Gene Therapy for Age-related Macular Degeneration Revenue Breakdown by Application (2018-2029)
3.3.5 Middle East and Africa Gene Therapy for Age-related Macular Degeneration Revenue Breakdown by Application (2018-2029)
4 Gene Therapy for Age-related Macular Degeneration Competition Analysis by Players
4.1 Global Gene Therapy for Age-related Macular Degeneration Market Size by Players (2018-2023)
4.2 Global Top Players by Company Type (Tier 1, Tier 2 and Tier 3) & (based on the Revenue in Gene Therapy for Age-related Macular Degeneration as of 2022)
4.3 Date of Key Players Enter into Gene Therapy for Age-related Macular Degeneration Market
4.4 Global Top Players Gene Therapy for Age-related Macular Degeneration Headquarters and Area Served
4.5 Key Players Gene Therapy for Age-related Macular Degeneration Product Solution and Service
4.6 Competitive Status
4.6.1 Gene Therapy for Age-related Macular Degeneration Market Concentration Rate
4.6.2 Mergers & Acquisitions, Expansion Plans
5 Company (Top Players) Profiles
5.1 RetroSense Therapeutics
5.1.1 RetroSense Therapeutics Profile
5.1.2 RetroSense Therapeutics Main Business
5.1.3 RetroSense Therapeutics Gene Therapy for Age-related Macular Degeneration Products, Services and Solutions
5.1.4 RetroSense Therapeutics Gene Therapy for Age-related Macular Degeneration Revenue (US$ Million) & (2018-2023)
5.1.5 RetroSense Therapeutics Recent Developments
5.2 REGENXBIO
5.2.1 REGENXBIO Profile
5.2.2 REGENXBIO Main Business
5.2.3 REGENXBIO Gene Therapy for Age-related Macular Degeneration Products, Services and Solutions
5.2.4 REGENXBIO Gene Therapy for Age-related Macular Degeneration Revenue (US$ Million) & (2018-2023)
5.2.5 REGENXBIO Recent Developments
5.3 AGTC
5.3.1 AGTC Profile
5.3.2 AGTC Main Business
5.3.3 AGTC Gene Therapy for Age-related Macular Degeneration Products, Services and Solutions
5.3.4 AGTC Gene Therapy for Age-related Macular Degeneration Revenue (US$ Million) & (2018-2023)
5.3.5 Recent Developments
6 North America
6.1 North America Gene Therapy for Age-related Macular Degeneration Market Size by Country (2018-2029)
6.2 U.S.
6.3 Canada
7 Europe
7.1 Europe Gene Therapy for Age-related Macular Degeneration Market Size by Country (2018-2029)
7.2 Germany
7.3 France
7.4 U.K.
7.5 Italy
7.6 Russia
7.7 Nordic Countries
7.8 Rest of Europe
8 Asia-Pacific
8.1 Asia-Pacific Gene Therapy for Age-related Macular Degeneration Market Size by Region (2018-2029)
8.2 China
8.3 Japan
8.4 South Korea
8.5 Southeast Asia
8.6 India
8.7 Australia
8.8 Rest of Asia-Pacific
9 Latin America
9.1 Latin America Gene Therapy for Age-related Macular Degeneration Market Size by Country (2018-2029)
9.2 Mexico
9.3 Brazil
9.4 Rest of Latin America
10 Middle East & Africa
10.1 Middle East & Africa Gene Therapy for Age-related Macular Degeneration Market Size by Country (2018-2029)
10.2 Turkey
10.3 Saudi Arabia
10.4 UAE
10.5 Rest of Middle East & Africa
11 Gene Therapy for Age-related Macular Degeneration Market Dynamics
11.1 Gene Therapy for Age-related Macular Degeneration Industry Trends
11.2 Gene Therapy for Age-related Macular Degeneration Market Drivers
11.3 Gene Therapy for Age-related Macular Degeneration Market Challenges
11.4 Gene Therapy for Age-related Macular Degeneration Market Restraints
12 Research Finding /Conclusion
13 Methodology and Data Source
13.1 Methodology/Research Approach
13.1.1 Research Programs/Design
13.1.2 Market Size Estimation
13.1.3 Market Breakdown and Data Triangulation
13.2 Data Source
13.2.1 Secondary Sources
13.2.2 Primary Sources
13.3 Disclaimer
13.4 Author List
Published By : QY Research
Why ‘The Market Reports’
In Business:
Pre Sales Support:
Post Sales Support:
Turn Around Time:
Clients Served:
Clients Assisted:
Client Types:
Payment:
- Accept global payments [Credit Card / PayPal / Wire Transfer]
- Accept local payments in South Korea, Germany, China and India [Can pay in local currency]
Latest Life Science Market Reports
Payments Accepted From
Connect with us at
Complete Secure Website
